Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06930508 · ClinicalTrials.gov registry record · NA
Bringing Medicines for HIV Prevention to a Family Planning Clinic
A NA study, sponsored by Women and Infants Hospital of Rhode Island.
- Recruiting
- Registry status
- NA
- Development phase
- 83
- Enrollment target
NCT06930508: Recruiting NA study, sponsored by Women and Infants Hospital of Rhode Island.
NCT06930508 is a NA study that is actively recruiting participants, run by Women and Infants Hospital of Rhode Island. The registered enrollment target is 83 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06930508, a NA study, is actively recruiting participants, sponsored by Women and Infants Hospital of Rhode Island.
- RECRUITING
- Registry status
- NA
- Development phase
- 83 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to understand what patients and physicians think about providing medications to prevent HIV transmission to patients in a family planning clinic. These medications are known as pre-exposure prophylaxis, or PrEP. The main questions to answer are: 1. Do patients find it acceptable to be asked about, and offered, PrEP during their visit to a family planning clinic? 2. What things make it easier or harder to ask about PrEP in a family planning clinic setting? 3. What things make it easier or harder to begin PrEP in a family planning clinic setting? Patient participants: 1. Will receive standardized counseling about PrEP. 2. Will have the opportunity to begin PrEP as part of their routine, ongoing care. 3. Will be asked to complete a survey about their experiences. Physician participants: 1. Will receive standardized education about PrEP. 2. Will talk to patient participants about PrEP, and support patient participants who want to begin PrEP. 3. Will be asked to complete pre-and post-study surveys about their experiences. 4. May be asked to complete a post-study in-depth interview about their experiences.
Primary Outcome
A validated measure of acceptability, administered via questionnaire. 4 Likert scale items. Item score range 1-5. Higher scores reflect higher acceptability.
Interventions
- BEHAVIORAL Patient participant screening
- BEHAVIORAL Physician participant training
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2026-05-28 |
| Est. Completion | 2026-07-31 |
| Phase | NA |
What NCT06930508 shows while recruiting
NCT06930508 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Patient participant screening is the first listed.
NCT06930508 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06930508 about?
NCT06930508 is a clinical study titled "Bringing Medicines for HIV Prevention to a Family Planning Clinic". The goal of this clinical trial is to understand what patients and physicians think about providing medications to prevent HIV transmission to patients in a family planning clinic. These medications are known as pre-exposure prophylaxis, or PrEP. The main questions to answer are: 1. Do patients fin...
What is the current status of trial NCT06930508?
This trial is currently recruiting. It is a NA study. The enrollment target is 83 participants. The study started on 2026-05-28. Estimated completion is 2026-07-31.
What interventions are being tested in trial NCT06930508?
The interventions under investigation include: Patient participant screening (BEHAVIORAL), Physician participant training (BEHAVIORAL).
Who is sponsoring clinical trial NCT06930508?
This trial is sponsored by Women and Infants Hospital of Rhode Island, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06930508's enrollment target sits among peer trials
83 990th of 2000 higher than 1,011 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI